About Reszon Diagnostics International Sdn. Bhd. (Reszon)Established since October 11th, 2010, Reszon Diagnostics International Sdn. Bhd. (Reszon), a member of Hextar Healthcare Berhad develops and manufactures a strong portfolio of innovative in-vitro diagnostics (IVD) rapid tests and enzyme-linked immunosorbent assay (ELISA) kits for medical professionals, including clinical diagnostic markets worldwide. Reszon’s IVD rapid test kits allow medical professionals to diagnose diseases quickly and accurately for the early detection and prevention of diseases. The ease of use and portability of its rapid test kits make them ideal for applications in a wide range of settings, including remote areas and countries where sophisticated medical diagnostics are not available. Reszon is actively transforming its manufacturing process to full automation in order to competitively address growing global needs. Reszon is also committed to providing the best affordable diagnostics in the self-testing sector.At present, Reszon has 3 manufacturing facilities located in Puchong and USJ Subang Jaya, Selangor with a current combined production capacity of approximately 96 million units of test kits annually. Since inception, we have strengthened our forte to put immunochromatographic assay development and innovation to commercial market. Driven by the motto of “Reasoning Possibilities in Life”, we remain our passions and commitment to create more possibilities through improving better health in human race.At Reszon, we continue to create solutions for healthcare institutions, laboratories, medical offices from all around the world. The test results derived from our testing device play acute role in point-of-care decision making, influencing majority of critical healthcare decisions for millions of people worldwide.VisionTo deliver better diagnostics solution to improve better health globallyMission· To be a global leading player in clinical diagnostics market· To produce and deliver top notch quality and cost effective diagnostic test kits· To constantly developing new immunodiagnostic tools with the most practical and innovative approachKey Achievements1. SALIXIUM COVID-19 Rapid Antigen Test (Oral/Nasal Swab Samples) are being included in the COVID-19 Care Package (PPC), which was announced by Malaysia government on 19 Sep 2021, expected to benefit about 3.6 million Keluarga Malaysia’s B40 families in preparation for the COVID-19 endemic phase2. Brugia Rapid – Endorsed by WHO for use in GPELF The Global Program to Eliminate Lymphatic Filariasis (GPELF) was initiated by WHO since year 2000 with the ultimate objectives to stop the spread of filariasis infection and to control morbidity through continuous collaborative effort worldwide. Filariasis diagnostic product, Brugia Rapid Test manufactured by Reszon is endorsed by WHO Technical Advisory Committee for use during transmission assessment survey (TAS) in several endemic countries such as Malaysia, Indonesia, Philippines, Vietnam and Sri Lanka. Through the use of our product as diagnostic tool, we hope that the correct intervention can be administered and hence helping to stop the spread of filariasis infection in affected countries.For more information on Reszon, please visit the following website: www.reszonics.com.
About Reszon Diagnostics International Sdn. Bhd. (Reszon)Established since October 11th, 2010, Reszon Diagnostics International Sdn. Bhd. (Reszon), a member of Hextar Healthcare Berhad develops and manufactures a strong portfolio of innovative in-vitro diagnostics (IVD) rapid tests and enzyme-linked immunosorbent assay (ELISA) kits for medical professionals, including clinical diagnostic markets worldwide. Reszon’s IVD rapid test kits allow medical professionals to diagnose diseases quickly and accurately for the early detection and prevention of diseases. The ease of use and portability of its rapid test kits make them ideal for applications in a wide range of settings, including remote areas and countries where sophisticated medical diagnostics are not available. Reszon is actively transforming its manufacturing process to full automation in order to competitively address growing global needs. Reszon is also committed to providing the best affordable diagnostics in the self-testing sector.At present, Reszon has 3 manufacturing facilities located in Puchong and USJ Subang Jaya, Selangor with a current combined production capacity of approximately 96 million units of test kits annually. Since inception, we have strengthened our forte to put immunochromatographic assay development and innovation to commercial market. Driven by the motto of “Reasoning Possibilities in Life”, we remain our passions and commitment to create more possibilities through improving better health in human race.At Reszon, we continue to create solutions for healthcare institutions, laboratories, medical offices from all around the world. The test results derived from our testing device play acute role in point-of-care decision making, influencing majority of critical healthcare decisions for millions of people worldwide.VisionTo deliver better diagnostics solution to improve better health globallyMission· To be a global leading player in clinical diagnostics market· To produce and deliver top notch quality and cost effective diagnostic test kits· To constantly developing new immunodiagnostic tools with the most practical and innovative approachKey Achievements1. SALIXIUM COVID-19 Rapid Antigen Test (Oral/Nasal Swab Samples) are being included in the COVID-19 Care Package (PPC), which was announced by Malaysia government on 19 Sep 2021, expected to benefit about 3.6 million Keluarga Malaysia’s B40 families in preparation for the COVID-19 endemic phase2. Brugia Rapid – Endorsed by WHO for use in GPELF The Global Program to Eliminate Lymphatic Filariasis (GPELF) was initiated by WHO since year 2000 with the ultimate objectives to stop the spread of filariasis infection and to control morbidity through continuous collaborative effort worldwide. Filariasis diagnostic product, Brugia Rapid Test manufactured by Reszon is endorsed by WHO Technical Advisory Committee for use during transmission assessment survey (TAS) in several endemic countries such as Malaysia, Indonesia, Philippines, Vietnam and Sri Lanka. Through the use of our product as diagnostic tool, we hope that the correct intervention can be administered and hence helping to stop the spread of filariasis infection in affected countries.For more information on Reszon, please visit the following website: www.reszonics.com.
About Reszon Diagnostics International Sdn. Bhd. (Reszon)Established since October 11th, 2010, Reszon Diagnostics International Sdn. Bhd. (Reszon), a member of Hextar Healthcare Berhad develops and manufactures a strong portfolio of innovative in-vitro diagnostics (IVD) rapid tests and enzyme-linked immunosorbent assay (ELISA) kits for medical professionals, including clinical diagnostic markets worldwide. Reszon’s IVD rapid test kits allow medical professionals to diagnose diseases quickly and accurately for the early detection and prevention of diseases. The ease of use and portability of its rapid test kits make them ideal for applications in a wide range of settings, including remote areas and countries where sophisticated medical diagnostics are not available. Reszon is actively transforming its manufacturing process to full automation in order to competitively address growing global needs. Reszon is also committed to providing the best affordable diagnostics in the self-testing sector.At present, Reszon has 3 manufacturing facilities located in Puchong and USJ Subang Jaya, Selangor with a current combined production capacity of approximately 96 million units of test kits annually. Since inception, we have strengthened our forte to put immunochromatographic assay development and innovation to commercial market. Driven by the motto of “Reasoning Possibilities in Life”, we remain our passions and commitment to create more possibilities through improving better health in human race.At Reszon, we continue to create solutions for healthcare institutions, laboratories, medical offices from all around the world. The test results derived from our testing device play acute role in point-of-care decision making, influencing majority of critical healthcare decisions for millions of people worldwide.VisionTo deliver better diagnostics solution to improve better health globallyMission· To be a global leading player in clinical diagnostics market· To produce and deliver top notch quality and cost effective diagnostic test kits· To constantly developing new immunodiagnostic tools with the most practical and innovative approachKey Achievements1. SALIXIUM COVID-19 Rapid Antigen Test (Oral/Nasal Swab Samples) are being included in the COVID-19 Care Package (PPC), which was announced by Malaysia government on 19 Sep 2021, expected to benefit about 3.6 million Keluarga Malaysia’s B40 families in preparation for the COVID-19 endemic phase2. Brugia Rapid – Endorsed by WHO for use in GPELF The Global Program to Eliminate Lymphatic Filariasis (GPELF) was initiated by WHO since year 2000 with the ultimate objectives to stop the spread of filariasis infection and to control morbidity through continuous collaborative effort worldwide. Filariasis diagnostic product, Brugia Rapid Test manufactured by Reszon is endorsed by WHO Technical Advisory Committee for use during transmission assessment survey (TAS) in several endemic countries such as Malaysia, Indonesia, Philippines, Vietnam and Sri Lanka. Through the use of our product as diagnostic tool, we hope that the correct intervention can be administered and hence helping to stop the spread of filariasis infection in affected countries.For more information on Reszon, please visit the following website: www.reszonics.com.